Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Other/Stem Cell Transplant

Stem Cell Transplant

33

Pipeline Programs↗

31

Active Trials↗

22

Companies Involved↗

Stem Cell Transplant is a moderately active landscape with 33 programs across 22 companies. The most active players are Bellicum Pharmaceuticals. 4 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

58/100

Pipeline Velocity

27/100

Mech. Concentration

11/100

Completion Rate

62/100

Attrition Rate

30/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Bellicum Pharmaceuticals

1 program

Pipeline

Programs by Phase

Preclinical3

Multivirus Specific T Cells

AlloVir

Ara-C

Karyopharm Therapeutics Inc

Campath 1h

Mario Negri Institute for Pharmacological Research

Phase 11

T-Allo10 Cells Addback

Porteus, Matthew, MD

Phase 225

Cyclophosphamide

Baxter Healthcare Corporation

Rimiducid

Bellicum Pharmaceuticals

BPX-501

Bellicum Pharmaceuticals

Methylprednisolone

Pfizer

Filgrastim

Eastern Cooperative Oncology Group

Phase 34

Melphalan

Apotex Inc.

Fludarabine Phosphate

Sanofi

Mycophenolate Mofetil

Roche

Posaconazole Pharmacokinetics

Melbourne Health

Approved

No programs

Analysis

Modality Breakdown

75%

Small molecule

24 of 32 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 32 classified programs, each share of the total. Modality classified for 100% of 33 pipeline programs.

Analysis

Trial Status

167

clinical trials

Completed81 · 49%

Terminated34 · 20%

Recruiting22 · 13%

Withdrawn16 · 10%

Active, not recruiting5 · 3%

Not yet recruiting4 · 2%

Other5 · 3%

Clinical Trials

Trial Activity

167 trials

Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant

Recruiting·UUniversity of Chicago·Phase 1·NCT02333162·30 enrolled

Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in Elderly PCNSL Patients

Recruiting·UUniversity Hospital Freiburg·Phase 3·NCT06830421·340 enrolled

Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant

Recruiting·UUniversity of Alabama at Birmingham·Phase 2·NCT06315309·29 enrolled

Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback

Recruiting·PPorteus, Matthew, MD·Phase 1·NCT04640987·22 enrolled

Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

Recruiting·HHenry Ford Health System·Phase 2·NCT03850418·43 enrolled

The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)

Recruiting·UUniversity of Leeds·Phase 3·NCT03562169·406 enrolled

Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial

Recruiting·IImperial College London·Phase 2·NCT06355583·50 enrolled

Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant

Recruiting·UUniversity of Alabama at Birmingham·Phase 2·NCT06265584·56 enrolled

Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults

Recruiting·—·N/A·NCT04249830·204 enrolled

Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants

Recruiting·MMelbourne Health·Phase 4·NCT03717623·100 enrolled

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

Recruiting·FFred Hutchinson Cancer Center·Phase 1/2·NCT06928662·36 enrolled

A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT05787574·39 enrolled

Study of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister Donor

Recruiting·JJeffrey Veale, MD·Phase 1/2·NCT03707262·15 enrolled

Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant

Recruiting·—·Phase 1/2·NCT03354728·80 enrolled

Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant

Recruiting·—·Phase 1/2·NCT06129734·20 enrolled

Page 1 of 12

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)